Study of AZD5305 as monotherapy and with anti-cancer agents in patients with advanced solid malignancies
- Conditions
- Advanced Solid TumorsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2020-002688-77-PL
- Lead Sponsor
- AstraZeneca AB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 1067
1Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
2Age = 18 at the time of screening
3Patients must have histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and meeting module specific eligibility criteria.
4Eastern Cooperative Oncology Group Performance status (ECOG) PS: 0-2 with no deterioration in the previous 2 weeks
5Life expectancy = 12 weeks
6Progressive cancer at the time of study entry
7Patients must have evaluable disease as per RECIST v1.1
8Female subjects of childbearing potential: Must have negative
pregnancy test result at screening and prior to each cycle administration of study treatment and must use at least one highly effective method of birth control plus a barrier method.
9Female subjects must not breastfeed and must not donate or retrieve ova for their own use, from screening to approximately 6 months after the last dose of study treatment with IMP.
10Male patients must use a condom with spermicide with all sexual
partners from screening to approximately 6 months after the last dose of AZD5305 IMP.
11. Adequate organ and marrow function as defined by the protocol.
12. For part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumour specimen is mandatory except if stated that it is optional in a specific Module.
Other module specific criteria may apply.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 939
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 128
1 Treatment with any of the following:
a Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment
b Any investigational agents or study drugs from a previous clinical
study within 5 half-lives or 3 weeks (whichever is shorter) of the first dose of study treatment
c Any other anticancer treatment within the time periods to the first dose of study treatment as indicated in the protocol
d Any live virus or bacterial vaccine within 28 days of the first dose of study treatment
2 Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 (CYP3A4) strong and moderate inhibitors or inducers.
3 Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes.
4 During the 4 weeks prior to the first dose, receiving continuous
corticosteroids at a dose of > 10 mg prednisone/day or equivalent for any reason.
5 Major surgery within 4 weeks of the first dose of study treatment.
6 Radiotherapy with a wide field of radiation within 4 weeks or
radiotherapy with a limited field of radiation for palliation within 2
weeks of the first dose of study treatment.
7 With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment.
8 Any history of persisting (> 2 weeks) severe pancytopenia due to any cause
9 Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded. Any evidence of severe or uncontrolled systemic diseases, including, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV. Screening for chronic conditions is not required.
10 Patients with any known predisposition to bleeding
11 Any of the following cardiac criteria
Mean resting corrected QT interval (QTcF) > 450 milliseconds or
QTcF<340 milliseconds
Any factors that increase the risk of QT prolongation, shortening or risk of arrhythmic events, congenital long or short QT syndrome, family history of long QT syndrome, familial short QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong or shorten the QT interval
Any clinically important abnormalities in rhythm, conduction or
morphology of resting ECG and clinically significant sinus node
dysfunction not treated with pacemaker.
12 Other cardiovascular diseases as defined by any of the following
(a) Symptomatic heart failure,
(b) uncontrolled hypertension,
(c) hypertensive heart disease with significant left ventricular
hypertrophy
(d) acute coronary syndrome (ACS)/acute myocardial infarction (AMI), unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6 months.
(e) cardiomyopathy of any etiology
(f) presence of clinically significant valvular heart disease
(g) history of atrial or ventricular arrhythmia requiring treatment;
subjects with atrial fibrillation/flutter and optimally controlled
ventricular rate (<100 beats per minute) are permitted
(h) transient ischaemic attack, or stroke within 6 months prior to
screening
(i) patients with symptomatic hypotension at screening
13 Patients with myelodysplastic syndrome/acu
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method